
RadioImmunotherapy is a process by which the radioisotope is attached to an antibody to specific tissue so it doesn't irradiate non-target tissue.  The radioisotope-antibody attaches itself to either the cancer tumor  or nearby tissue, and not to normal tissue in the rest of the body.  This will result in a high local dose to cancer tumors, and less radiation exposure to normal tissue.  In a pilot study, Yttrium-90 was attached [conjugated] to a monoclonal antibody [this is an antibody to one specific target] to part of a cancer cell [in this case glioma].   This 'radio-immuno conjugate' was injected into recurrent tumors.  There was prolonged retention of the isotope by the tumor cavity, with low activity in the bloodstream.  Doses and dose rates to the tumor were very high compared to normal tissue doses. [25]

For More Information:

&&url

Search Pubmed for &&url
